BeiGene Ltd ADR buy marge
Start price
01.01.19
/
50%
€120.88
Target price
04.11.21
€250.00
Performance (%)
166.39%
End price
05.11.21
€322.00
Summary
This prediction ended on 05.11.21 with a price of €322.00. The BUY prediction by marge for BeiGene Ltd ADR saw massive gains of 166.39%. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| BeiGene Ltd ADR | 3.425% | 3.425% | 32.456% | 36.036% |
| iShares Core DAX® | 0,39 % | 0,15 % | 10,96 % | 58,44 % |
| iShares Nasdaq 100 | 1,31 % | -2,55 % | -0,61 % | 84,24 % |
| iShares Nikkei 225® | -0,46 % | 6,89 % | 26,75 % | 63,40 % |
| iShares S&P 500 | 1,31 % | -1,16 % | -0,04 % | 58,22 % |
Comments by marge for this prediction
In the thread Beigene Ltd ADR diskutieren
BeiGene is a Buy, as the stock is currently over 25% off its high!
Validation came in the form of a global collaboration deal signed with Celgene to commercialize PD-1 inhibitor BGB-A137. The specifics of the deal were interesting, with BeiGene management wisely
licensing rights in China to Celgene's next generation CelMod for lymphoma and hepatocellular carcinoma, CC-122. The financial terms were very generous, with BeiGene to receive upfront licensing fees of $263 million. The larger firm purchased 32.7 million shares at $59.55 per ADS (a 35% premium over the 11-day volume-weighted average price at the time).
Kursziel geändert auf 220,0
Kursziel geändert auf 250,0
In the thread Trading Beigene Ltd ADR
Die von marge gewählte maximale Laufzeit wurde überschritten